Cancer-associated venous thromboembolism
AA Khorana, N Mackman, A Falanga… - Nature reviews Disease …, 2022 - nature.com
Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …
events) is highly consequential for patients with cancer and is associated with worsened …
Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system
S Gritsch, TT Batchelor, LN Gonzalez Castro - Cancer, 2022 - Wiley Online Library
The 2016 revised fourth edition of the World Health Organization (WHO) classification of
central nervous system (CNS) tumors incorporated molecular features with histologic …
central nervous system (CNS) tumors incorporated molecular features with histologic …
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
IK Mellinghoff, M Lu, PY Wen, JW Taylor, EA Maher… - Nature medicine, 2023 - nature.com
Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and
have shown preliminary clinical activity against m IDH glioma. We evaluated both agents in …
have shown preliminary clinical activity against m IDH glioma. We evaluated both agents in …
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017
Abstract The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration
with the Centers for Disease Control (CDC) and National Cancer Institute (NCI), is the …
with the Centers for Disease Control (CDC) and National Cancer Institute (NCI), is the …
Management of glioblastoma: State of the art and future directions
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
DNA methylation profiling: an emerging paradigm for cancer diagnosis
A Papanicolau-Sengos, K Aldape - Annual Review of Pathology …, 2022 - annualreviews.org
Histomorphology has been a mainstay of cancer diagnosis in anatomic pathology for many
years. DNA methylation profiling is an additional emerging tool that will serve as an adjunct …
years. DNA methylation profiling is an additional emerging tool that will serve as an adjunct …
The implications of IDH mutations for cancer development and therapy
CJ Pirozzi, H Yan - Nature reviews Clinical oncology, 2021 - nature.com
Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …
Diffuse glioma heterogeneity and its therapeutic implications
JG Nicholson, HA Fine - Cancer discovery, 2021 - AACR
Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …
characterized by minimally effective genotype-targeted therapies. Recent advances have …
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018
Abstract The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration
with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute …
with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute …
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate
and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances …
and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances …